The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

Romosozumab shows bone mineral density gain in postmenopausal women with severe osteoporosis, irrespective of prior exposure ...

Researchers suggest bisphosphonate could potentially reduce the risk of colorectal cancer, but more randomized trials should be carried out to confirm their results, according to an Internal Medicine ...

Some of the most commonly used medications for osteoporosis can lead to osteonecrosis of the jaw (ONJ), a rare but serious side effect.

Data suggest a protective association of bisphosphonates against having a kidney stone diagnosis or procedure. Patients receiving bisphosphonates for osteoporosis treatment are less likely to have ...

Bisphosphonates have long been established as critical agents in the treatment of bone disorders, yet recent innovations in their green synthesis are paving the way for more sustainable, efficient, ...

Denosumab (Prolia) is a leading treatment for osteoporosis, but the rapid bone loss that can occur after discontinuing the RANK ligand inhibitor can be challenging to navigate. "I don't think we have ...